Meet the Proteona team at the 37th Annual J.P. Morgan HEALTHCARE CONFERENCE in San Francisco
Innovative genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
Proteona announced that Dr. Andreas Schmidt, Chief Executive Officer, will be at the 37th Annual J.P. Morgan HEALTHCARE CONFERENCE in San Francisco from the 7th to the 10th January, 2019.
Dr. Schmidt will be available during the conference to discuss the recent development in their ESCAPE™ RNA Sequencing technology, which allows for obtaining protein and gene expression information from the same single cells.
For media queries, please contact:
Dr. Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).